Isotopia to Expand Terbium-161 Production for Targeted Cancer Therapies

Jerusalem, 3 June, 2025 (TPS-IL) — Israeli company Isotopia Molecular Imaging has signed a supply deal with ASP Isotopes to secure Gadolinium-160, a key material for producing Terbium-161, a promising new isotope for targeted cancer therapies. Isotopia will use the material at its facility in Petach Tikva to expand production of Terbium-161, which is being tested for treating prostate cancer and other tumors.

Isotopia also plans to start production in the U.S., expanding its international reach in the fast-growing radiopharmaceutical sector.